Tissue engineering basics

In short

Tissue engineering combines cells, a scaffold and biochemical or mechanical signals to grow living substitutes that restore, maintain or improve tissue function — the classic "tissue engineering triad". It sits between biomaterials science (what the scaffold is made of) and clinical medicine (what the graft must do), and it matters because transplantable organs and autografts are scarce while degenerative disease is not. In Indian B.E./B.Tech biomedical and biotech syllabi it appears as a full unit, and in GATE Biomedical Engineering (BM) and GATE Biotechnology (BT) it is examined through scaffold properties, cell-culture kinetics, mass transfer and porosity calculations. Employers include SCTIMST Thiruvananthapuram and its TIMed facility, inStem/CCMB/NCCS laboratories, Stempeutics Research (Bengaluru), Advancells, HCG and Apollo cell-therapy units, Pandorum Technologies, and device firms building scaffolds and bioreactors; regulatory roles work to the National Guidelines for Stem Cell Research (2017, ICMR-DBT) and the New Drugs and Clinical Trials Rules, 2019 under CDSCO.

Explained

The tissue engineering triad and what each element does

• Cells supply the biological function — they secrete matrix, remodel it and respond to signals. Sources: autologous (patient's own; no rejection, but a second surgery and delay), allogeneic (another human; off-the-shelf, immune risk), xenogeneic (animal; immune and zoonosis risk).
• Scaffold (matrix) is the temporary 3-D template: it holds cells in place, defines the shape of the new tissue, carries mechanical load while the tissue is weak, and then degrades.
• Signals are the soluble and physical cues: growth factors, oxygen tension, pH, and mechanical stimulation (shear, cyclic strain, compression) delivered in a bioreactor.
• Approaches: (i) cells alone (injected suspensions, islet transplantation); (ii) scaffold alone, acellular, relying on host cells to invade (guided tissue regeneration); (iii) cells + scaffold cultured before implantation — the full construct.
• In vitro vs in situ: *in vitro* engineering matures the tissue in a bioreactor then implants it; *in situ* implants an acellular scaffold and uses the body as the bioreactor — cheaper and far easier to regulate.

Cells and stem cells

• Differentiated (primary) cells: chondrocytes for cartilage, keratinocytes and fibroblasts for skin, hepatocytes, osteoblasts. Limited expansion; chondrocytes de-differentiate in monolayer culture.
• Stem cell classes by potency: *totipotent* (zygote — whole organism plus placenta), *pluripotent* (embryonic stem cells, iPSCs — all three germ layers), *multipotent* (mesenchymal stem cells — bone, cartilage, fat, muscle), *unipotent* (one lineage).
• MSCs are the workhorse in India: sourced from bone marrow, adipose tissue, umbilical cord/Wharton's jelly and dental pulp; easy to expand, immunomodulatory, no embryo ethics issue.
• iPSCs: adult somatic cells reprogrammed with transcription factors (Oct4, Sox2, Klf4, c-Myc). Patient-specific and pluripotent, but carry teratoma and genomic-instability risk.
• Culture basics: monolayer passaging, trypsinisation, passage number (phenotype drifts with passage), confluence, doubling time, Hayflick limit for primary cells. Media are DMEM/F-12 type with serum (FBS) or defined serum-free formulations.
• Differentiation cues: osteogenic (dexamethasone, β-glycerophosphate, ascorbate, BMP-2), chondrogenic (TGF-β3, insulin), adipogenic (IBMX, indomethacin), plus substrate stiffness — soft gels (~1 kPa) favour neurogenic, stiff (~30 kPa) osteogenic lineages.

Scaffolds: requirements, materials and fabrication

• Design requirements: biocompatible and non-immunogenic; interconnected porosity (typically >80-90% for soft tissue) with pore size matched to the tissue (roughly 100-400 µm for bone ingrowth and vascularisation, ~20-80 µm for skin/fibroblast infiltration — ranges differ between textbooks, so quote them as approximate); surface chemistry that supports cell adhesion; degradation rate matched to tissue regeneration; mechanical strength near the host tissue; sterilisable; reproducible and economic to make.
• Natural polymers: collagen, gelatin, fibrin, chitosan, alginate, hyaluronic acid, silk fibroin (strong Indian research base). Excellent cell recognition (RGD motifs), weak and batch-variable mechanically.
• Synthetic polymers: PLA, PGA, PLGA (degradation tuned by lactide:glycolide ratio), PCL (slow, months to years), PEG hydrogels, PHBV. Reproducible and tunable, but degrade by bulk hydrolysis releasing acidic monomers that can lower local pH and cause inflammation.
• Ceramics and composites: hydroxyapatite, tricalcium phosphate, bioactive glass (45S5) and BHA/PLGA composites for bone — osteoconductive, brittle alone.
• Decellularised matrix (dECM): native tissue stripped of cells by detergents (SDS, Triton X-100), enzymes (trypsin, DNase) or physical means, leaving collagen-laminin architecture and the native vascular tree. Used for heart valves, small intestinal submucosa, trachea and whole-organ scaffolds; residual DNA must be below accepted thresholds (commonly cited as <50 ng dsDNA per mg dry ECM).
• Fabrication methods: solvent casting/particulate leaching (porogen = salt or sugar); gas foaming; freeze-drying (lyophilisation) — ice crystals become pores; thermally induced phase separation; fibre bonding; electrospinning — a polymer jet drawn by 10-30 kV into nanofibres that mimic ECM fibre scale; melt extrusion and fused deposition; 3-D printing / bioprinting (extrusion, inkjet, laser-assisted, stereolithography) for patient-specific geometry from CT/MRI data; self-assembling peptide hydrogels.
• Hydrogels: crosslinked hydrophilic networks (alginate-Ca²⁺ ionic, PEG-diacrylate photo-crosslinked, gelatin methacryloyl). Injectable, cell-friendly, highly permeable; mechanically weak, so poor for load-bearing sites.

Cell seeding, mass transfer and bioreactors

• Static seeding (pipetting a suspension onto the scaffold) is simple but gives low, non-uniform efficiency and a cell-rich shell with a dead core; dynamic seeding (orbital, spinner flask, perfusion, centrifugal, vacuum) gives higher efficiency and uniformity.
• The oxygen diffusion limit is the central constraint: cells survive roughly 100-200 µm from a capillary or culture medium, so a construct thicker than a few hundred microns needs convection or a vasculature. This is why skin and cartilage (thin, avascular) reached the clinic first and liver and kidney have not.
• Bioreactor types: spinner flask (convection at the surface, high shear), rotating-wall vessel (microgravity-like, low shear, free suspension), direct perfusion (medium forced through the scaffold — best internal mass transfer), hollow-fibre, and mechanical-stimulation reactors (cyclic compression for cartilage, pulsatile flow for vessels, cyclic strain for tendon).
• Mechanotransduction: cells sense flow shear, hydrostatic pressure and strain through integrins, focal adhesions, the cytoskeleton, primary cilia and stretch-activated ion channels; loading raises matrix output markedly — pulsatile conditioning is standard for engineered blood vessels.
• Vascularisation strategies: pro-angiogenic factor delivery (VEGF, bFGF), co-culture with endothelial cells, sacrificial-channel printing, dECM vascular trees, and arteriovenous-loop prevascularisation in vivo.
• Growth-factor delivery: bolus doses have short half-lives (minutes to hours), so factors are encapsulated in microspheres, covalently tethered, bound through heparin, or supplied by gene-modified cells for sustained release.

Degradation, mechanics and characterisation

• Degradation mechanisms: hydrolysis (polyesters), enzymatic (collagen by collagenase, chitosan by lysozyme), oxidative, and dissolution (calcium phosphates). Bulk erosion weakens the whole scaffold at once; surface erosion (polyanhydrides, polyorthoesters) keeps the core strong.
• Design rule: the scaffold must lose strength no faster than the new tissue gains it; too fast collapses the construct, too slow causes stress shielding and a chronic foreign-body response.
• Characterisation routinely examined: SEM and micro-CT for pore size, porosity and interconnectivity; mercury intrusion/liquid displacement porosimetry; tensile and compressive testing for modulus; DSC/TGA for thermal behaviour; FTIR and XRD for chemistry and crystallinity; contact angle for wettability; swelling and *in vitro* degradation (mass loss in PBS at 37 °C); GPC for molecular-weight loss.
• Biological assays: MTT/XTT and Alamar Blue for viability, live-dead staining, LDH for membrane damage, Alizarin Red (calcium) and ALP for osteogenesis, Safranin-O and GAG assay for cartilage, immunostaining, qPCR for lineage markers, DNA content for cell number.
• Biocompatibility testing follows the ISO 10993 series (cytotoxicity 10993-5, sensitisation 10993-10, irritation 10993-23, implantation 10993-6, degradation 10993-13), adopted in India as IS/ISO 10993 parts.

Clinical applications, limitations and the Indian regulatory frame

• In clinical use: cultured epidermal autografts and collagen-based skin substitutes for burns; autologous chondrocyte implantation and matrix-induced ACI for cartilage defects; bone grafts of hydroxyapatite/TCP ± BMP; limbal stem-cell transplantation for corneal surface disease (Indian centres including LVPEI Hyderabad and Sankara Nethralaya are world-recognised in cultivated limbal epithelial transplantation); decellularised heart valves and dermal matrices; bone-marrow and cord-blood haematopoietic transplants.
• Research stage: engineered liver, kidney, pancreas (islet encapsulation), myocardial patches, trachea, nerve conduits, organoids and organ-on-chip models for drug testing.
• Limitations: no vasculature at useful thickness, cost and logistics of cell manufacture (GMP clean rooms, cold chain), limited cell supply, immune and tumorigenic risk with pluripotent cells, poor scaffold mechanics for load-bearing use, batch-to-batch variability, and difficult long-term regulation.
• Indian regulation: the National Guidelines for Stem Cell Research, 2017 (ICMR-DBT) govern research — all work needs IC-SCR oversight and the national apex committee NAC-SCRT; except haematopoietic stem-cell transplantation for approved indications, all other stem-cell use is investigational and must go through a clinical trial — marketing stem-cell "therapy" outside a trial is not permitted. Human embryonic stem-cell derivation and germline modification are restricted, and reproductive cloning is prohibited.
• Product route: cell-based products are regulated as new drugs by CDSCO/DCGI under the New Drugs and Clinical Trials Rules, 2019 (with the National Biopharma/ CDSCO-DBT guidance documents on cell and gene therapy products); biomedical research on humans follows the ICMR National Ethical Guidelines (2017) with Institutional Ethics Committee registration. A scaffold with no cells and no drug action may instead be a medical device under the Medical Devices Rules, 2017, which risk-classify devices A-D (a resorbable implant is typically Class C or D) and require manufacturing/import licences from CDSCO. Which route applies depends on the product's principal mode of action — classification is decided case by case, so confirm current CDSCO guidance for any specific product.
• ATMP/clean-room practice: cell manufacture needs ISO 14644 classified areas, validated cryopreservation (10% DMSO, controlled-rate freezing, liquid nitrogen), traceability and sterility/mycoplasma/endotoxin release testing.

Key points

• Tissue engineering triad - cells + scaffold + signals, assembled to restore tissue function.
• Autologous vs allogeneic - own cells avoid rejection but add a surgery and weeks of delay; donor cells are off-the-shelf but immunogenic.
• Scaffold roles - template for shape, temporary load carrier, cell-adhesion surface, controlled-release depot, then it must disappear.
• Porosity and pore size - high interconnected porosity for nutrient flow and ingrowth; ~100-400 µm suits bone and vessels, smaller pores suit soft tissue.
• Porosity-strength trade-off - every increase in porosity lowers modulus and strength, roughly as a power law.
• Natural vs synthetic polymers - natural ones are cell-friendly but weak and variable; synthetic ones are reproducible and tunable but bioinert and acid-releasing on degradation.
• PLGA tuning - more glycolide means faster hydrolysis; 50:50 degrades in weeks, PCL in a year or more.
• Decellularisation - removes cells and nuclear material while preserving collagen architecture and the vascular tree; residual DNA is the key release test.
• Electrospinning - high voltage draws nanofibres whose diameter mimics native ECM collagen, giving a huge surface-to-volume ratio.
• Hydrogels - injectable, highly permeable, cytocompatible; mechanically unsuited to load bearing.
• Oxygen diffusion limit - ~100-200 µm from a supply; this, not biology, caps construct thickness and forces vascularisation.
• Perfusion bioreactor - forces medium through the scaffold, giving the most uniform cell distribution and matrix production.
• Mechanical conditioning - cyclic load or pulsatile flow signals cells through integrins and raises matrix synthesis.
• Degradation matching - strength loss of the scaffold must track strength gain of the new tissue.
• Bulk vs surface erosion - bulk erosion collapses mechanically mid-life; surface erosion retains a strong core.
• ISO 10993 - the biological evaluation series (cytotoxicity, sensitisation, implantation, degradation) used for scaffold safety.
• NGSCR 2017 + NAC-SCRT/IC-SCR - Indian oversight; only HSCT for approved indications is standard care, everything else is a trial.
• CDSCO route - cell-based products are new drugs under the NDCT Rules, 2019; acellular scaffolds may fall under the Medical Devices Rules, 2017 by principal mode of action.

Formulas and examples

Example 1 - Porosity and modulus of a PLGA scaffold. A freeze-dried PLGA scaffold disc is 12 mm diameter × 4 mm thick and weighs 32 mg dry. Bulk PLGA density = 1.30 g/cm³, bulk modulus = 2.0 GPa.

• Apparent volume V = π r² h = 3.1416 × (0.6 cm)² × 0.4 cm = 3.1416 × 0.36 × 0.4 = 0.4524 cm³.
• ρ_scaffold = 0.032 g / 0.4524 cm³ = 0.0707 g/cm³.
• Relative density = 0.0707/1.30 = 0.0544 → ε = 1 − 0.0544 = 0.9456 ≈ 94.6 % porosity.
• Gibson-Ashby: E = 2.0 GPa × (0.0544)² = 2.0 × 0.00296 GPa = 5.9 MPa.
• Comment: 94.6 % porosity is excellent for nutrient transport but ~6 MPa is far below cortical bone (~15-20 GPa) — this scaffold suits soft tissue or a non-load-bearing filler, not a load-bearing bone defect.

Example 2 - Expansion of MSCs: how many passages are needed? A bone-marrow aspirate yields 5 × 10⁵ MSCs. A 20 cm³ construct must be seeded at 2 × 10⁷ cells/cm³. Doubling time = 36 h.

• Cells required N = 2 × 10⁷ × 20 = 4 × 10⁸.
• Fold expansion = 4 × 10⁸ / 5 × 10⁵ = 800×.
• Population doublings PD = log₂(800) = ln800/ln2 = 6.6846/0.6931 = 9.64 doublings.
• Time = 9.64 × 36 h = 347 h = 14.5 days of pure exponential growth; with trypsinisation lag and media changes, realistically 4-6 weeks.
• Comment: ~10 doublings is within the safe window for MSCs (senescence and karyotype drift become a concern beyond roughly 15-20 doublings), but the delay is why autologous constructs cannot treat acute trauma.

Example 3 - Oxygen diffusion limit in a cell-laden hydrogel slab. Medium-facing hydrogel slab, cells at 1 × 10⁸ cells/cm³ (= 1 × 10¹⁴ cells/m³), per-cell consumption q = 2 × 10⁻¹⁷ mol/cell·s, D = 2 × 10⁻⁹ m²/s, surface C₀ = 0.20 mol/m³.

• Volumetric consumption Q = 1 × 10¹⁴ × 2 × 10⁻¹⁷ = 2 × 10⁻³ mol/m³·s.
• L_crit = √(2 D C₀ / Q) = √(2 × 2 × 10⁻⁹ × 0.20 / 2 × 10⁻³) = √(8 × 10⁻¹⁰ / 2 × 10⁻³) = √(4 × 10⁻⁷) = 6.32 × 10⁻⁴ m = 632 µm half-thickness.
• So a slab fed from both faces can be about 1.26 mm thick before the centre hits zero oxygen; halve the safety margin for a real tissue and you are back to a few hundred microns.
• Comment: dropping the cell density to 1 × 10⁷ cells/cm³ lowers Q tenfold → L_crit = √(4 × 10⁻⁶) = 2.0 mm — lower seeding density buys thickness but gives less tissue function.

Example 4 - Seeding efficiency, static vs perfusion. 2 × 10⁶ cells are seeded onto each of two identical scaffolds. After 6 h, the static scaffold retains 7.0 × 10⁵ cells and the perfusion-seeded scaffold 1.70 × 10⁶.

• Static η = 7.0 × 10⁵ / 2 × 10⁶ = 35 %; perfusion η = 1.70 × 10⁶ / 2 × 10⁶ = 85 %.
• Cells needed to place 1 × 10⁶ cells: static 1 × 10⁶/0.35 = 2.86 × 10⁶; perfusion 1 × 10⁶/0.85 = 1.18 × 10⁶ — a 2.4× saving in precious autologous cells.

Example 5 - Electrospun mat: fibre surface area and degradation half-life. An electrospun PCL mat has ε = 0.90 and fibre diameter 500 nm.

• S_v = 4(1 − ε)/d_f = 4 × 0.10 / (5 × 10⁻⁴ mm) = 0.4/0.0005 = 800 mm²/mm³ = 8 × 10⁵ m²/m³ — roughly 100× the area of a 50 µm-fibre mesh at the same porosity, which is why nanofibres adsorb far more adhesion protein.
• If Mw falls from 80 kDa to 40 kDa in 24 weeks by first-order hydrolysis: k = ln2/24 = 0.0289 per week; Mw at 52 weeks = 80 × e^{−0.0289×52} = 80 × e^−1.503 = 80 × 0.2225 = 17.8 kDa — below the ~10-20 kDa range where mechanical integrity is normally lost.

Where it is used

• Clinical burns and wound care: cultured skin substitutes and collagen dressings in burns units and plastic surgery; Indian suppliers of collagen-based wound matrices and amniotic membrane grafts.
• Orthopaedics and dentistry: hydroxyapatite and β-TCP bone-graft substitutes, guided bone-regeneration membranes, demineralised bone matrix — manufactured in India by implant and dental-material firms and used in arthroplasty revision and periodontal surgery.
• Ophthalmology: cultivated limbal epithelial transplantation and amniotic-membrane scaffolds at LVPEI, Sankara Nethralaya and AIIMS — one of India's genuine world-leading contributions.
• Cell-therapy industry and GMP manufacturing: roles in process development, clean-room QA, cryobanking and regulatory affairs at firms such as Stempeutics, Advancells and cord-blood banks; SCTIMST (a national institute under DST) for device-grade biomaterials and its TIMed incubator for start-ups.
• Research and academic positions: project staff and PhD positions at inStem, NCBS, CCMB, NCCS, IITs (Bombay, Kanpur, Madras, Guwahati) and NITs on scaffolds, bioprinting and organoids, funded by DBT/BIRAC, SERB and ICMR.
• Pharma and CRO testing: 3-D tissue models, liver spheroids and organ-on-chip platforms used for toxicity screening, increasingly relevant as regulators accept non-animal methods.

Interview questions

• Q: What are the three components of the tissue engineering triad? A: Cells, a scaffold or matrix, and signals — growth factors plus physical and mechanical cues; all three must be matched to the target tissue.
• Q: Why is the oxygen diffusion limit the central problem in tissue engineering? A: Cells survive only about 100-200 µm from a nutrient supply, so without a vasculature or perfusion a construct thicker than a fraction of a millimetre develops a necrotic core — which is why skin and cartilage succeeded clinically and liver has not.
• Q: How do you choose the pore size of a scaffold? A: By the tissue: larger pores (roughly 100-400 µm) allow capillary and bone ingrowth, smaller pores suit fibroblast infiltration and give more surface area for adhesion; the choice always trades mechanical strength against transport.
• Q: Compare PLGA and PCL as scaffold materials. A: PLGA hydrolyses in weeks to a few months with the rate set by the lactide:glycolide ratio and releases acidic by-products; PCL is far slower (a year or more), more flexible and better for long-term constructs.
• Q: Why might a degrading polyester scaffold cause inflammation? A: Bulk hydrolysis releases lactic and glycolic acid faster than the tissue can clear it, lowering local pH and triggering an inflammatory and foreign-body response.
• Q: What does decellularisation achieve and what is its key quality test? A: It removes cellular and nuclear antigens while preserving the collagen architecture and vascular tree; residual DNA content (commonly a limit of under about 50 ng dsDNA per mg dry ECM) plus absence of visible nuclei on staining are the usual criteria.
• Q: Why are MSCs preferred over embryonic stem cells in Indian practice? A: They are easy to harvest from marrow, fat or cord, expand readily, are immunomodulatory, carry no teratoma risk and avoid the ethical and regulatory restrictions that apply to human embryonic stem cells.
• Q: Which bioreactor would you choose to make a uniform 5 mm thick bone construct, and why? A: A direct perfusion bioreactor — it forces medium through the interconnected pores, giving uniform oxygen and nutrient delivery plus a shear stimulus that promotes osteogenic matrix deposition.
• Q: What is the regulatory position of stem-cell therapy in India? A: Under the National Guidelines for Stem Cell Research, 2017, only haematopoietic stem-cell transplantation for approved indications is standard care; everything else is investigational and must run as an approved clinical trial, with IC-SCR and NAC-SCRT oversight and CDSCO approval under the New Drugs and Clinical Trials Rules, 2019.
• Q: An acellular collagen wound matrix — drug or device in India? A: It depends on the principal mode of action: with no cells and no pharmacological action it is normally handled as a medical device under the Medical Devices Rules, 2017 (risk class typically C or D for an implant), while a cell-containing product goes down the new-drug route; classification is confirmed with CDSCO case by case.
• Q: Why does increasing porosity reduce strength, and how much? A: Less solid material carries the load and the struts buckle; for an open-cell foam the Gibson-Ashby relation gives modulus falling with the square of relative density, so 90 % porosity leaves roughly 1 % of the bulk modulus.
• Q: Why is mechanical stimulation applied to engineered cartilage and blood vessels? A: Cells sense strain and shear through integrins and the cytoskeleton and respond by increasing matrix synthesis and aligning it, so cyclic compression raises GAG content in cartilage and pulsatile flow builds burst strength in vessels.

Common mistakes

• Treating "biocompatible" as a property of the material alone — it depends on the site, the duration, the degradation products and the host response, and must be shown by ISO 10993 testing.
• Reporting porosity but not interconnectivity: closed pores contribute to the porosity figure and nothing to transport or ingrowth.
• Designing for maximum porosity and ignoring the resulting collapse in modulus (the Gibson-Ashby square law).
• Forgetting that the scaffold's degradation rate must be matched to tissue regeneration — exams specifically test "too fast" and "too slow" failure modes.
• Assuming a cell-seeded construct can simply be scaled up in thickness; without vascularisation the core dies.
• Confusing potency terms (totipotent / pluripotent / multipotent) and claiming MSCs can make any tissue.
• Stating that stem-cell therapy is approved treatment in India for conditions beyond haematopoietic transplantation — it is investigational and trial-only under the 2017 guidelines.

Related topics

Biomaterials and biocompatibility · Artificial organs and implants · Medical device design and development · Cell and molecular biology for engineers · Bioreactor design and bioprocess engineering · Biomechanics and kinesiology